Iron Deficiency Anemia Therapy Market Report 2026

Iron Deficiency Anemia Therapy Market Overview

• Iron Deficiency Anemia Therapy market size has reached to $4.78 billion in 2025 • Expected to grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Rise In Chronic Diseases Fueling The Growth Of The Market Due To Increasing Demand For Supportive Treatment • Market Trend: Advancements In Injectable Formulations To Enhance Iron Deficiency Anemia Treatment Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Iron Deficiency Anemia Therapy Market?

Iron-deficiency anemia therapy involves a multifaceted approach aimed at replenishing iron levels in the body to restore healthy red blood cell production. The primary goal is to address the underlying cause of iron deficiency, whether through dietary adjustments, supplementation, or, in some cases, medical interventions. The main product types of iron deficiency anemia therapy include ferrous sulfate, ferrous gluconate, ferrous fumarate, and ferric hydroxide. Ferrous sulfate refers to a commonly used iron supplement in the treatment of iron deficiency anemia. These are used for various therapy types, including parenteral iron therapy, oral iron therapy, red blood cell transfusion, and others. The various therapy areas include inflammatory bowel diseases, renal diseases, obstetrics and gynecology, congestive heart failure, and oncology, and it is distributed through various distribution channels such as hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. It is used by various end users such as hospitals, specialty clinics, home care settings, and others.

What Is The Iron Deficiency Anemia Therapy Market Growth Forecast?

The iron deficiency anemia therapy market size is expected to see strong growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for faster anemia correction, rising incidence of chronic diseases causing anemia, expansion of specialty anemia clinics, growing focus on maternal and pediatric anemia care, advancements in iron formulation technologies. Major trends in the forecast period include increasing adoption of intravenous iron therapies, rising demand for targeted anemia treatments, growing focus on patient-specific therapy regimens, expansion of oral and parenteral combination therapies, enhanced emphasis on treatment efficacy and safety.

Global Iron Deficiency Anemia Therapy Market Segmentation

1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide 2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types 3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology 4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users Subsegments: 1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations 2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations 3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups 4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations

What Is The Driver Of The Iron Deficiency Anemia Therapy Market?

Increasing cases of chronic diseases are expected to propel the growth of the iron deficiency anemia therapy market going forward. Chronic diseases refer to medical conditions that are long-lasting in nature and typically persist for a year or more. The rise in chronic diseases can be attributed to the increasing prevalence of unhealthy lifestyles, including poor diet, lack of physical activity, and smoking, which contribute to conditions such as obesity, diabetes, and heart disease, resulting in long-term health complications. Chronic conditions can increase the need for iron deficiency anemia therapy by hindering the body's ability to absorb iron properly, raising the risk of iron deficiency, and necessitating supplementation or treatment to restore iron levels. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia in 2023, or pre-diabetes, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing cases of chronic diseases are driving growth in the iron deficiency anemia therapy industry.

Key Players In The Global Iron Deficiency Anemia Therapy Market

Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc, Abbott Laboratories, Bayer AG, Pfizer Inc., Lupin Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd.

Global Iron Deficiency Anemia Therapy Market Trends and Insights

Major companies operating in the iron deficiency anemia therapy market are focusing on developing advancements in treatment options, such as injectable formulations, to enhance treatment efficacy and accessibility. New injectable formulation refers to a newly developed or modified version of a drug that is administered via injection. For instance, in May 2023, Emcure Pharmaceuticals Ltd., an Indian-based pharmaceutical company, launched Orofer FCM 750, a formulation of ferric carboxymaltose (FCM) designed to treat iron deficiency and iron deficiency anemia (IDA). Its benefits include improved patient compliance due to less frequent administration compared to oral supplements. The purpose is to effectively treat iron deficiency anemia, especially in individuals who cannot tolerate oral iron supplements. It is a 750 mg/15 ml injectable ferric carboxymaltose approved by India’s DCGI for iron deficiency anemia (IDA) in patients unresponsive to oral iron, particularly pregnant women with hemoglobin <10 g/dl and weight 35–70 kg, offering a 15-minute infusion (diluted in saline) and alignment with Anemia Mukt Bharat guidelines as a first-line treatment for severe cases.

What Are Latest Mergers And Acquisitions In The Iron Deficiency Anemia Therapy Market?

In March 2025, Hyloris Pharmaceuticals, a Belgium-based pharmaceutical company, partnered with AFT Pharmaceuticals to co-develop HY‑094, an injectable therapy for iron deficiency anemia. Through this collaboration, the companies aim to advance Phase III clinical trials and jointly commercialize HY‑094 globally, with Hyloris leading European commercialization and AFT managing markets outside Europe. This partnership underscores the iron deficiency anemia therapy market’s growing focus on innovative, clinically advanced injectable treatments and global co-development strategies. AFT Pharmaceuticals, a New Zealand-based developer of specialty medicines.

Regional Outlook

North America was the largest region in the iron deficiency anemia therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Iron Deficiency Anemia Therapy Market?

The iron deficiency anemia therapy market consists of revenues earned by entities by providing services such as iron supplementation, diagnostic services, nutritional counseling, home healthcare services, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia therapy market also includes sales of oral iron supplements, intravenous (IV) iron preparations, erythropoiesis-stimulating agents, iron-fortified foods, and blood transfusion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.